Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5130450 | 0.76 | TRPV1 (0.78) | TRPV1MAPK3 | |
| SCHEMBL4358042 | 0.75 | TRPV1 (0.62) | TRPV1MAPK3 | |
| SCHEMBL4075406 | 0.74 | TRPV1 (0.46) | TRPV1MAPK3 | |
| SCHEMBL5118591 | 0.74 | TRPV1 (0.75) | TRPV1MAPK3 | |
| SCHEMBL5128105 | 0.74 | TRPV1 (1.00) | TRPV1MAPK3 | |
| SCHEMBL4076189 | 0.74 | TRPV1 (0.58) | TRPV1MAPK3 | |
| SCHEMBL12501034 | 0.72 | TRPV1 (0.44) | TRPV1MAPK3 | |
| SCHEMBL1860193 | 0.71 | TRPV1 (0.45) | TRPV1MAPK3 | |
| SCHEMBL2648851 | 0.70 | RPS6KB1 (0.36) | TRPV1 | |
| SCHEMBL5118586 | 0.70 | TRPV1 (0.47) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
| CN-101103028-A | Heteroaryl substituted quinolin-4-ylamine analogues | NEUROGEN CORP (US) | 2008-01-09 | — | — | CN | disclosed |
| EP-1836203-A2 | HETEROARYL SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006076646-A2 | HETEROARYL SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | PIGS, GPR52, GPR174 | TRPV1 477/4885MAPK3 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.